The cardiovascular benefits of weekly injected GLP-1 receptor agonists have been proven in SUSTAIN-6 (Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes), REWIND (Researching Cardiovascular Events with a Weekly Incretin in Diabetes) and The Harmony outcomes trials. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.